Microbix Biosystems Inc. · TSX:MBX
Microbix Biosystems — Investor Presentation (November 2026)
28 slides from Microbix Biosystems's investor presentation, Nov 17, 2026
Slide 1: Advancing Global Health By Supporting Next-Generation Diagnostics
MICROBIX PRESENTATION Advancing Global Health By Supporting Next-Generation Diagnostics Autumn 2026 TSX: MBX | OTCQX: MBXBF
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements about trends and objectives. Risks and uncertainties relating to such statements could cause actual outcomes to differ materially. Such risks include, among others, those related to operations, customers or markets, gro
Slide 3: Microbix – Supporting Next-Generation Diagnostics
Microbix – Supporting Next-Generation Diagnostics Established Global Diagnostics Addition of Higher-Value, Stabilized Base, Positioned for Supplier Faster-Growing QAPs Growth • 30+ year track record supplying • Expanding quality assessment & • F2026 expected revenue of $16- antigens to 100+ diagnost
Slide 4: Microbix – Supporting Next-Generation Diagnostics (Continued)
Microbix – Supporting Next-Generation Diagnostics (Continued) Strong Financial Position Built for Scale Aligned Capital Allocation Enables Execution • ~$11M in total liquidity (cash + • 3 facilities + automation + • >12.5 M shares repurchased unused credit); low leverage regulatory infrastructure ac
Slide 5: Financials – Microbix Capital Structure
Financials – Microbix Capital Structure TSX: MBX • OTCQX: MBXBF Current Price $0.295 (2026-11-13) 1-Year Share Price Nov 17, 2025 – Nov 13, 2026 $0.34 Shares Outstanding (Basic) 137.2M** $0.30 (Fully Diluted) 168.5M** $0.26 $0.22 52 Week High $0.325 $0.18 52 Week Low $0.21 Daily volume $40.5M Nov '2
Slide 6: Experienced Leadership Team with Deep Diagnostics & Commercial Expertise
Experienced Leadership Team with Deep Diagnostics & Commercial Expertise Cameron L. Groome Jim Currie, CPA Ken Hughes, Ph.D. CEO, President, and Director Chief Financial Officer Chief Operating Officer • Has served on the MBX BoD and AC since • Joined MBX as CFO in 2016 after several • Executive and
Slide 7: Microbix Board of Directors
Microbix Board of Directors Experienced Board with Deep Healthcare, Pharma, and Governance Expertise Martin Marino Dr. Peter M. Blecher Mark A. Cochran, Ph.D. Vaughn C. Embro-Pantalony Board Chairman Director HRGC Chair AC Chair Mr. Marino has 30+ years of Dr. Blecher, a longtime ER Dr. Cochran was
Slide 8: Two Complementary Product Lines Supporting Global Diagnostics
Two Complementary Product Lines Supporting Global Diagnostics Established base business with growing exposure to higher-value quality controls Antigen Sales - established base business (C$ We grow, purify, and inactivate many bacteria 1,000s) and viruses to make “Antigens,” as critical $16,000 ingre
Slide 9: Established Core Business with Deep Customer Integration
TEST INGREDIENTS – ANTIGENS Established Core Business with Deep Customer Integration Grows, purifies, and inactivates native bacteria and viruses for use as antigens for more than 100 leading international diagnostic companies. Microbix provides antigens on a large scale for major international diag
Slide 10: A higher-value, recurring segment of the diagnostics market
TEST CONTROLS – QUALITY ASSESSMENT PRODUCTS (QAPS ) A higher-value, recurring segment of the diagnostics market What QAPs Actually Do: Simulate real patient samples (e.g., as liquids, swabs, or tissue) to validate Dx assay performance. This is used across many QMS purposes, including for certifying
Slide 11: Microbix is a Trusted Partner Across The Global Diagnostics Ecosystem
Microbix is a Trusted Partner Across The Global Diagnostics Ecosystem Microbix has been supporting international test makers for Over recent years, Microbix has added new categories of decades – its Antigens forming the heart of millions of customers via its QAPs, expanding its addressable markets I
Slide 12: Where Microbix Products are Used
Where Microbix Products are Used World Map of Antigen and QAPs Distribution Our Ingredients (Antigens) and Medical Devices (QAPs) are in use around the world. Microbix products are available in more than 30 countries, directly or via partners. Countries where Microbix products are available TSX: MBX
Slide 13: Makers, Regulators, Users, & Payors Need Proof They Work
ENSURING CONFIDENCE IN DIAGNOSTIC TESTS Makers, Regulators, Users, & Payors Need Proof They Work Our Products Help Ensure that Tests Actually Microbix makes essential products that enable diagnostic Work. This is Critical for Correct Diagnosis tests to be made and sold. Many next-generation Dx assay
Slide 14: Kinlytic® – FDA-Approved, Fully Funded Drug with a Defined Path to Market
Kinlytic® – FDA-Approved, Fully Funded Drug with a Defined Path to Market Microbix owns the BLA of a well-established thrombolytic drug. Partnered with Sequel Pharma, LLC for re-launch of cell-culture derived LMW urokinase Kinlytic® Urokinase Microbix’s deep expertise in cell-culturing led to its se
Slide 15: Kinlytic® – An FDA-Approved Clot-Buster Drug
Kinlytic® – An FDA-Approved Clot-Buster Drug Refined project scope to first address the Sequel Pharma, LLC has secured 100% Catheter Clearance Indication & its U.S. funding of ~US$ 35M to fully underwrite total market as initial value-driver project cost & risk Multiple contacts with US FDA, and the
Slide 16: Scaled Manufacturing & Regulatory Infrastructure to Support Growth
Scaled Manufacturing & Regulatory Infrastructure to Support Growth Significant capacity in place to support revenue expansion without major incremental capital We Have Built Both Capabilities and Capacity To Secure New Product & Customer Opportunities Built for Scale: Regulatory & Integrated Product
Slide 17: Scaled Manufacturing Capacity Ready for Growth
Scaled Manufacturing Capacity Ready for Growth We Have Built Both Capabilities and Capacity To Secure New Product & Customer Opportunities QAP Production Automation & Product Development Capacity Efficiency & Expansion • Liquid vial format: • Semi-automated and • Dedicated R&D and QC ~150,000 units/
Slide 18: Operations - Expanding Product Line & Revenue
Operations - Expanding Product Line & Revenue Microbix’s product line is rapidly expanding, as is our base of customers. Just in the past months… – Welcomed The College of American Pathologists (CAP) as a QAPs February 2026 client – to support multiple EQA/PT programs. – For Kinlytic urokinase clot-
Slide 19: Microbix – The Past 10 Years at a Glance
2017 – 2026 Microbix – The Past 10 Years at a Glance 2017 2018 2019 2020 2021 New CEO & Recapitalization Facility Upgrades 2nd Site Leased for QAPs COVID QAP Launched (March Viral Transport Medium Creation Reinvestment into sales-driven Material upgrades to 265 Watline To expand mfg. of QAPs (235 20
Slide 20: Financials – The Past Several Years
FINANCIAL RESULTS – 2021 TO 2026 Financials – The Past Several Years Revenues, Current Ratio¹, Net Earnings, and EBITDA¹ Have Repurchased (& cancelled) over 12.5 Million Shares C$ millions; fiscal years end Sept 30; full-year totals under each year Q1 Q2 Q3 Q4 REVENUE CURRENT RATIO¹ 8.45 7.15 8.48 6
Slide 21: Clear Path to Revenue Growth and Product Mix Expansion
Clear Path to Revenue Growth and Product Mix Expansion Leveraging existing relationships, expanding product adoption, and entering new markets 1. Expand Within Existing Customers • Cross-sell QAPs into >100 existing 2. Add New High-Value Customers • Target diagnostic Cos. with >$1M annual diagnostic
Slide 22: Key Takeaways about Microbix
Key Takeaways about Microbix Microbix has become a “go-to” 1. Established Diagnostics Platform with Global Customers • Trusted supplier to 100+ diagnostic companies, EQA providers, and labs partner regarding next-generation diagnostic tests. Its QAPs are often • Embedded in the global diagnostics ec
Slide 23: Thank You
Thank You Cameron Groome CEO, President, and Director cameron.groome@microbix.com TSX: MBX | OTCQX: MBXBF
Slide 24: Appendix regarding non-GAAP Financial Measures
Appendix regarding non-GAAP Financial Measures This appendix provides important context concerning the Management believes the EBITDA (non-GAAP) financial non-GAAP financial measure “EBITDA” referenced on slides measure may assist investors in assessing an investment in 3 and 19 earlier herein. the
Slide 25: Appendix regarding non-GAAP Financial Measures (Continued)
Appendix regarding non-GAAP Financial Measures (Continued) Quantitatively, EBITDA as defined above may be reconciled Debt-to-Equity, also known as D/E, is a financial ratio to IFRS-defined and reported Net Earnings by the deduction comprised of the firm’s total debt over its shareholders’ from EBITD
Slide 26: Appendix regarding non-GAAP Financial Measures (Continued)
Appendix regarding non-GAAP Financial Measures (Continued) Reconciliation of Non-GAAP (non-IFRS) Measure Quarterly EBITDA Fiscal 2021 to 2026 2021 Q1 Q2 Q3 Q4 FY Total 2022 Q1 Q2 Q3 Q4 FY Total Net Income (Loss) $130,819 $807,463 $1,516,178 $778,930 $3,233,390 Net Income (Loss) $880,778 $733,489 $63
Slide 27: Appendix regarding non-GAAP Financial Measures (Continued)
Appendix regarding non-GAAP Financial Measures (Continued) Reconciliation of Non-GAAP (non-IFRS) Measure Quarterly EBITDA Fiscal 2021 to 2026 2023 Q1 Q2 Q3 Q4 FY Total Net Income (Loss) ($1,299,262) $31,616 ($769,108) $1,997,271 ($39,483) Interest 97,078 91,319 102,490 90,749 381,636 Taxes - - - - D
Slide 28: Appendix regarding non-GAAP Financial Measures (Continued)
Appendix regarding non-GAAP Financial Measures (Continued) Reconciliation of Non-GAAP (non-IFRS) Measure Quarterly EBITDA Fiscal 2021 to 2026 2025 Q1 Q2 Q3 Q4 FY Total Net Income (Loss) $856,962 $20,664 ($1,642,776) ($1,480,662) ($2,245,812) Interest 113,129 157,962 156,489 168,314 595,894 Taxes - -
Microbix Biosystems — Investor Presentation (November 2026) on 6ix